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Abstract With the refinement of algorithms for the identifica-
tion of distinct motifs from sequence databases, especially those
using secondary structure predictions, new protein modules have
been determined in recent years. Calponin homology (CH)
domains were identified in a variety of proteins ranging from
actin cross-linking to signaling and have been proposed to
function either as autonomous actin binding motifs or serve a
regulatory function. Despite the overall structural conservation
of the unique CH domain fold, the individual modules display a
quite striking functional variability. Analysis of the actopaxin/
parvin protein family suggests the existence of novel (type 4 and
type 5) CH domain families which require special attention, as
they appear to be a good example for how CH domains may
function as scaffolds for other functional motifs of different
properties. ß 2002 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The 100 amino acid calponin (CaP) homology (CH) do-
main is one of about a dozen protein domains which are
shared by both signaling and cytoskeletal proteins. Whilst a
repeating pattern, now known to be equivalent to the VH
domain, had been identi¢ed in a number of actin binding
proteins [1] the de¢nitive description of the CH module by
Matti Saraste’s group in 1995 [2] caused workers in the ¢eld
to take a closer look at previously described actin binding
domains (ABDs). The division of ABDs into two dissimilar
CH domains (an N-terminal or type 1 CH domain and a
C-terminal or type 2 CH domain) helped to explain di¡er-
ences observed in the actin binding a⁄nities of the two sepa-
rated CH domains of the K-actinin ABD, but also provided a
paradox in terms of explaining the presence of a CH domain
which may not be involved in actin binding.
Banuelos et al. [3], using a structural approach to shed
more light on this puzzle postulated an auxiliary function
for the second CH domain in an ABD. As a general rule
(and yes, there is also an exception to it) one can assume
that if a protein displays two CH domains in tandem they
likely form an ABD. This hypothesis appears to be close to
the biological truth since reports are now accumulating in
which the second, but not the ¢rst, CH domain in an ABD
displays additional functions, some unrelated to the ‘primary’
function, namely actin binding. However, a tandem array it-
self may not be su⁄cient for the formation of an actin binding
interface, but appears to require the conjunction of a type 1
and a type 2 CH domain. Functional heterogeneity in CH
domains is well-documented in the CH domains of the
K-actinin ABD as regards their actin binding abilities. In ad-
dition, recent ¢ndings have revealed a novel function of CH
domains: they also contain speci¢c binding sites for proteins
and phosphoinositides.
The CH domain is de¢ned by a number of almost invariant
core residues. These core residues are likely to be the major
factors involved in stabilising the three-dimensional (3D)
structure. The conservation of these residues in CH domains
throughout species points towards an evolutionarily conserved
structure. Yet, functional diversity is the prevailing theme in
CH domains. This is best re£ected by the single (type 3) CH
domains which can be found in a large and diverse family of
proteins, which contains both cytoskeletal and signaling pro-
teins. The actin binding ability of type 3 CH domains in iso-
lation is still questionable. However, a number of other func-
tions have been postulated for this module. Here we will
discuss the current ideas concerning the structural, functional
and evolutionary aspects of CH domains. We will describe the
structural parameters, which de¢ne a CH domain, propose a
nomenclature for the distinction of CH domains and analyse a
few of the recent developments relevant to the biological func-
tion(s) of CH domains.
2. Type 1 and type 2 CH domains in ABDs
The type 1 and type 2 CH domains together form the actin
binding region of a large number of F-actin interacting pro-
teins, involved in a variety of cytoskeleton and cytoskeleton^
membrane linkages. This ranges from actin binding/bundling
proteins, like K-actinin, spectrin and ¢lamin, cytolinkers con-
necting F-actin to other ¢lament networks, like spectrin, plec-
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tin and dystonin, and proteins connecting the actin cytoskel-
eton to various membrane-associated proteins including cell
adhesion receptors (e.g. dystrophin, utrophin). In all cases the
canonical type 1/2 CH domain-containing ABD is an e⁄cient
F-actin binding domain with an a⁄nity for F-actin in the low
WM range with no other signi¢cant e¡ect on actin dynamics
and to all intents and purposes functionally equal. However,
several of these proteins have the ability to dimerise. When
this happens, these proteins can now crosslink actin ¢laments
(e.g. K-actinin, spectrin and ¢lamin). Beyond the ability to
bind to F-actin, a multitude of further functions is conferred
by one or more of the many other protein^protein interaction
modules present in these often large and complex proteins
(Fig. 1).
2.1. CH1 versus CH2
Whilst the ABDs as a whole are functionally equivalent, in
as much as they interact with F-actin with V5^50 WM a⁄n-
ity, the CH domains they comprise are functionally distinct
[4]. Type 1 CH domains have the intrinsic ability to interact
with F-actin whilst type 2 CH domains do not. In all cases so
far examined (K-actinin, L-spectrin, dystrophin, utrophin), the
type 1 CH domain alone has an a⁄nity for F-actin in the
region of 10-fold lower than the complete actin binding region
comprising both CH domains, whilst the type 2 CH domain
does not bind actin at all [5^7]. Clearly, however, despite the
type 2 CH domain having no intrinsic actin binding activity, it
contributes substantially to the interaction of the complete
actin binding domain, perhaps by acting as a locator or low
a⁄nity docking site on the actin ¢lament. Such a role has also
been proposed for the type 3 CH domain of CaP, which also
lacks intrinsic actin binding activity (see below). Despite this
functional di¡erence, where structures are known for the ca-
nonical type 1/2 CH domains, there is little to choose between
them on a structural basis. The functional di¡erence therefore
must come down to discrete sequence elements exposed on the
potential actin binding surfaces of these molecules. A consid-
erable e¡ort has been put into identifying such sequences and
work from a number of laboratories (see [8] and references
therein) has identi¢ed three regions within the ABDs as im-
Fig. 1. The superfamily of CH domain-containing molecules. All entries are human, with the exception of cortexillin and interaptin which are
unique for Dictyostelium discoideum. Light blue ribbons symbolise multiple (n) copies of identical domains. The Simple Modular Architecture
Research Tool (SMART) which is available at http://smart.embl-heidelberg.de is an easy-to-use, rapid and reliable source for identifying CH
domain proteins and for obtaining total domain organisations of proteins.
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portant for actin binding. These have been termed actin bind-
ing sites (ABS) 1^3 from N to C terminus and correspond to:
helix A in the type 1 CH domain; the loop and helices F and
G in the type 1 CH domain; helix A in type 2 CH domain
(Fig. 2). As the stoichiometry of actin binding by these ABDs
is 1:1 rather than 3:1 it was predicted that these three ABSs
would come together in the tertiary structure to form a single
actin binding interface on the surface of the ABD [6]. Whilst
this did not quite turn out to be true (see below) the three
ABSs do all appear to participate in F-actin binding, at least
in the case of utrophin [9].
2.2. Structural conservation versus functional plasticity
The architecture of the CH domain is dominated by four
K-helices (A, C, E and G) (Fig. 3), comprising 11^18 residues
and connected by long loops. Three short and less regular
helices (B, D and F) are minor secondary structure elements.
The structure can be described in terms of three layers, the
core being composed of two parallel K-helices (C and G),
which are sandwiched on one side by helix E, and on the
other side by the N-terminal helix A. This sca¡olding is mark-
edly di¡erent from the known 3D structures of actin severing,
capping or regulating proteins such as gelsolin, villin, severin,
pro¢lin and destrin, which are characterised by a central
L-sheet sandwiched between one or more K-helices. The 3D
structure of the CH domain can be analysed with respect to
the conservation of key residues and its predicted actin bind-
ing activity. A very conserved region of the molecule is helix
C, which builds the hydrophobic core of the protein. This
segment belongs to a sequence pro¢le that has been used
for detection of CH domains in proteins [2].
The recently published crystal structures of dystrophin, ¢m-
brin, spectrin and utrophin CH domains have shed consider-
able light on several aspects of CH domain function but in-
evitably also raised questions [7,8,10^12]. The ABDs of
dystrophin and utrophin crystallised as antiparallel dimers
with the two CH domains in a relatively extended or open
conformation [8,12], whereas ¢mbrin was a more compact
monomer in the crystal with the two CH domains closely
associated [10]. The orientation of the CH domains in the
utrophin crystal, however, was such that the type 1 and
type 2 CH domains from each of the separate chains in the
crystal dimer closely resembled the orientation of the 2 CH
domains in the single chain in the ¢mbrin crystal. Utrophin
and dystrophin ABDs are known to be monomeric in solu-
tion, indeed whole puri¢ed dystrophin^glycoprotein complex
does not exhibit any actin bundling activity suggesting it too
is monomeric for dystrophin at least [13,14], and so the utro-
phin and dystrophin dimers in the crystal are likely to be an
artefact of crystallisation. The preservation of an interface
between two domains in monomeric (¢mbrin) and oligomeric
forms (utrophin and dystrophin) is a phenomenon known as
3D domain swapping (reviewed in [15]). This suggests there-
fore that in solution, dystrophin and utrophin are likely to
adopt a conformation similar to ¢mbrin, with the type 1 and
type 2 CH domains in close apposition. This, however, does
not ¢t with the recent cryo-electron microscopy reconstruc-
tions of utrophin with F-actin, which show utrophin interact-
ing with F-actin in the more open conformation adopted by
utrophin in the crystal [9]. This raises the exciting and as yet
untested hypothesis that utrophin, and perhaps all type 1/2
CH domains, undergo a dramatic conformational change
Fig. 2. Sequence alignment and secondary structure cartoon of K-actinin, L-spectrin, utrophin and dystrophin with annotation of ABS1^3 and
the PIP2 binding site.
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upon interaction with F-actin. The same cannot be said of
¢mbrin, however (see below).
A large number of biochemical studies using mutagenesis,
cross-linking and spectroscopy have implicated three segments
(de¢ned above as ABS 1, 2 and 3) of an actin binding region
in actin binding. These amino acids are mostly hydrophobic,
which agrees with the current paradigm that the force driving
the interaction with actin ¢laments is at least in part hydro-
phobic. The combination of available biochemical informa-
tion and structural analysis suggests that the protein surface
centred around the last helix of the ¢rst CH domain, and
probably spanning to the N-terminus of the second CH do-
main is essential for actin binding. The importance of this
area may explain why the a⁄nity of the isolated type 1 CH
domain for actin is one order of magnitude lower than that of
the complete actin binding region. Amino acid sequence anal-
ysis of residues in ABSs (ABS 1, 2, 3) of the actin binding
regions shows that the characteristic pattern of conserved res-
idues on the molecular surface is only conserved in the type 1
and type 2 CH domains. This is of course in line with its clear
biological function, binding to actin ¢laments. The signal is
lost in type 3^5 CH domains (see below) suggesting their
functional diversity and/or alternative modes of interaction
with actin ¢laments.
2.3. Regulation
In common with many other actin binding proteins, it has
been known for some time that the actin binding properties of
some K-actinin isoforms and ¢mbrin can be regulated by cal-
cium. In the case of K-actinin and spectrin this is achieved by
virtue of the presence of EF hand regions present in these
molecules rather than any direct e¡ect of Ca2 on the CH
domains themselves. Several other mechanisms have evolved
for the direct regulation of type 1/2 CH domain interaction
with actin. K-Actinin in the muscle Z-line was shown to con-
tain bound phosphatidylinositol (4,5)-bisphosphate (PIP2)
[16], furthermore in non-muscle cells actin-associated K-acti-
nin contained bound PIP2 whereas cytosolic K-actinin was
free of PIP2, suggesting that PIP2 activated the actin bundling
activity of K-actinin [17]. The PIP2 binding site on K-actinin
was delineated as a 17 amino acid region immediately C-ter-
minal of the ABS3 [18] (see Fig. 2). Precisely how PIP2 bind-
ing to this site promotes actin binding is not known. If
K-actinin associates with F-actin in an orientation similar to
utrophin [9], with which it shares over 50% sequence identity
(and presumably also high structural homology) then this re-
gion of K-actinin would be expected to be in the F-actin inter-
face and PIP2 would be more likely to inhibit actin binding
than promote it. Indeed, PIP2 binding to both ¢lamin and
dystrophin does inhibit their interactions with F-actin
[19,20] though the precise binding sites in either of these mol-
ecules are unknown and the physiological signi¢cance is un-
certain. The precise mechanistic details of how PIP2 promotes
actin bundling by K-actinin also remain to be elucidated, but
the di¡erence between K-actinin and dystrophin and ¢lamin
may be due to the immediate environment of the CH do-
mains, which in the K-actinin dimer includes the EF hands
from the opposing antiparallel dimer.
The special situation in K-actinin is further underscored by
the identi¢cation of DFRXXL-like motifs in the molecule,
one (DFRXXL) immediately adjacent to ABS 1 in the helix
B^helix C turn, the other (DFRXXL in K-actinin 2 and 3;
EFKXXL in K-actinin 1 and 4) embedded in the predicted
EF-hand sequences at the C-terminus of the molecule. The
DFRXXL motif has been shown to constitute a novel actin
binding motif which links myosin light chain kinase (MLCK)
to the actin ¢lament by occupying a novel interface along the
¢lament [21,22]. The antiparallel dimerisation of K-actinin
likely brings the C-terminal motif in close proximity of the
N-terminal CH domain-based motif. Future studies will have
to address the in£uence of this motif in the regulation of
K-actinin binding to actin.
Fig. 3. Ribbon presentations of the molecular architecture of the L-spectrin type 2 CH domain as seen perpendicular (a) and parallel (b) to the
two core K-helices C and G. Colour coding ranges from violet for N-terminal to red for the C-terminal residues. Ribbon diagrams were gener-
ated using programs Molscript [54], and Raster3d [55].
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Calmodulin has also been shown to regulate the interaction
of dystrophin, utrophin and K-actinin ABDs with F-actin
through direct binding to the CH domains, though again
the physiological relevance of this is not clear [23^26]. Most
recently it has been shown that K-actinin is phosphorylated on
tyrosine at position 12 by focal adhesion kinase (FAK) and
that FAK phosphorylation of K-actinin reduces its a⁄nity for
F-actin [27]. Interestingly, however, this tyrosine phosphory-
lation lies N-terminal of the ¢rst CH domain in a variable
region of di¡ering length found in all type 1/2 CH domain
ABDs. It has previously been noted that the amino terminal
extension of the utrophin ABD was somehow important for
actin binding a⁄nity, as monoclonal antibodies raised against
this region inhibited actin binding [28] and deletion of this 28
amino acid variable region in utrophin reduced actin binding
a⁄nity Vfour-fold [8].
2.4. Smoothelin: single type 2 CH domains?
Smoothelin is a cytoskeletal protein speci¢cally expressed in
di¡erentiated smooth muscle cells and has been shown to
colocalise with smooth muscle K-actin. In addition to the
small smoothelin isoform of 59 kDa, a larger isoform of
117 kDa and several alternatively spliced isoforms have also
been described. Smoothelins harbour a single CH domain at
Fig. 4. Phylogenetic tree of CH domain proteins as in Fig. 1. More detailed information about core residues, subclassi¢cations, helix^loop bor-
ders, sequence alignments and more can also be obtained at http://server1.imolbio.oeaw.ac.at/mgimona/. GenBank accession codes (all entries
are human, except where otherwise noted): Type 1/type 2: (1) P12814, K-actinin 1; (2) P35609, K-actinin 2; (3) Q08043, K-actinin 3; (4)
XP_048404, ¢lamin 1; (5) XP_030806, L-¢lamin; (6) XP_045856, Q-¢lamin; (7) XP_039511, L-spectrin; (8) Q15149, plectin 1; (9) Q9UPN3,
ACF7; (10) P11532, dystrophin; (11) P46939, utrophin; (12) AAC50243, dystonin isoform 1; (13) BAB59010, calmin; (14) AAC34582, interap-
tin (D. discoideum) ; (15) AAB62275, cortexillin I (D. discoideum) ; (16) AAB62274, cortexillin II (D. discoideum). Type 2 only: (17) CAA90281,
smoothelin-A; (18) CAA73884, smoothelin-B. Type 3: (1) P_005419, Vav 1; (2) Q9UKW4, Vav 3; (3) XP_005638, Vav 2; (4) BAA04985,
ARHGEF6; (5) JS0774, SM22; (6) Q9UI15, NP25; (7) XP_032793, CaP h1; (8) Q99439, CaP h2; (9) Q15417, acidic CaP; (10) P46940, IQ-
GAP1; (11) genbank:NP_006624, IQGAP 2. Type 4/type 5: (1) XP_043987, K-parvin; (2) XP_043616, L-parvin; (3) XP_043623, Q-parvin. Fim-
brin-type: P13797, T-plastin. EB type: (1) CAA63923, T-cell activation protein; (2) BAA82958, EB3 protein.
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their C-termini, which displays the closest sequence similarity
with the type 2 CH domain of K-actinin, L-spectrin and ¢la-
min. There are no reports available describing actin binding of
smoothelin and the protein itself appears to form a ¢lamen-
tous network [29]. It is not clear at this point whether or not
smoothelin can bind directly to actin, and if the type 2 CH
domain is involved in any of the described functions or in the
molecule’s subcellular localisation.
2.5. Fimbrin
Although ¢mbrin does not strictly contain a type1/2 CH
domain ABD it does have an ABD that contains canonical
CH domains and will be discussed here for completeness. By
virtue of the large inter-helical loops within the CH domains
of ¢mbrin, the four CH domains present within the two ABDs
of ¢mbrin fall into their own distinct classes (Fig. 4). Further-
more the large inter-CH domain linker in ¢mbrin also sets it
aside from the classical type 1/2 CH domain ABD found in
K-actinin and homologues (see also below). Nevertheless, the
large amount of biochemical as well as structural information
from both crystallographic and cryo-electron microscopy re-
constructions has made ¢mbrin a useful model for CH do-
main F-actin interactions [10,30^32]. Unlike utrophin and
dystrophin, ¢mbrin appears to associate with F-actin in a
more compact conformation [31,32]. There doesn’t appear
to be any requirement for the ¢mbrin CH domains to adopt
a more extended arrangement. This may be because the length
of the ¢mbrin inter-CH domain linker is long enough to allow
a stable interface between the two CH domains of the ABD,
or due to the fundamental di¡erences in the ¢mbrin CH do-
mains per se, allowing ¢mbrin simply to interact with actin via
a di¡erent mechanism. The combined data on the atomic
modeling of human T-¢mbrin from Hanein et al. [32] and
the reported discrepancy in Kd values for the plant AtFim1
[33] substantiate a di¡erent mode of interfacing with the actin
¢lament for the two ABDs in ¢mbrin. In addition to actin
binding, Correia et al. [34] described an interaction of ¢mbrin
with the intermediate ¢lament protein vimentin via the ¢rst
CH domain. Based on the location of this binding site on
¢mbrin, the molecule was implicated in the regulation of vi-
mentin assembly, an important feature which appears to be
repeated in the interaction of the CH domain of CaP with
desmin (see below) and thus pointing towards a possibly con-
served functional inter-relationship between CH domain pro-
teins and intermediate ¢lament proteins.
2.6. EB-family proteins
A single CH domain with highest sequence similarity to the
second (type 2?) CH domain of the C-terminal ABD of ¢m-
brin has been identi¢ed in the APC-binding, microtubule plus-
end localised protein EB1 and its relatives EB2 and EB3 (see
Fig. 1). These molecules harbour the CH module close to their
respective N-termini. There is too little experimental data on
the protein to hypothesise about the function of its CH do-
main but, considering the possibility of intermediate ¢lament
interaction of ¢mbrin-type CH domains and the reported lo-
calisation of EB proteins, it is tempting to speculate on an
involvement of the EB CH domains in tubulin interactions.
Experiments are underway testing the consequences of CH
domain deletion and exchange on the APC-binding and mi-
crotubule targeting of EB1.
3. Inter-CH domain sequences
In K-actinin-like molecules the sequences separating the two
CH domains are almost negligible as they span a mere six
residues and may simply contribute to the helix (G) connect-
ing the ¢rst and second CH domain. Thus, the 3D structure of
a type 1/type 2 CH domain ABD may be viewed rather as a
unit than as a tandem array of individual modules. Fimbrin,
however, di¡ers in this respect. Although it contains a tandem
CH domain ABD and strongly binds and bundles actin, the
CH domains are so unique that there is a strong likelihood for
alternative functions. Moreover, the spacer sequences are lon-
ger than those found in K-actinin. Since the inter-CH domain
linker sequence in the second ABD of ¢mbrin is almost four
times longer than that of the ¢rst one, we may expect the
identi¢cation of further new (regulatory?) functions for this
domain in the future. Calmin, enaptin and NUANCE (and
possibly also interaptin) are novel proteins with a C-terminal
transmembrane domain and a classical type 1/type 2 ABD,
but there is little functional data available as regards their
actin binding capacity. What is noteworthy, however, is the
unusually long serine-rich inter-CH domain linker, which ex-
ceeds that of ¢mbrin. The longest spacer sequences are the 60
residue inter-CH domain linkers of the actopaxin/parvin fam-
ily. However, as discussed below, it is questionable if this
stretch indeed separates the two halves of a functional ABD
(separating ABS 2 and 3) or if this region is more similar to
that found between the two ABDs in ¢mbrin.
4. Single (type 3) CH domains in cytoskeletal and signaling
molecules
CaP family proteins form a separate branch in the phylo-
genetic tree of CH domains, together with (almost all) other
proteins containing a single CH domain (Vav, IQGAP, ARH-
GEF6, SM22; see Figs. 1 and 4). Furthermore, the predicted
or experimentally identi¢ed functions of the CH domains in
this family di¡er markedly from the type 1 and type 2 mod-
ules and have therefore been classi¢ed as type 3 CH domains.
4.1. CaP family proteins
In contrast to the actin cross-linking and bundling proteins
described above, CaP contains only a single CH domain,
which shares little sequence similarity with type 1 or type 2
CH domains. CaP binds to ¢lamentous actin in the absence of
the amino terminal CH domain both in vitro and in vivo.
Conversely, isolated CH domains fail to associate with F-actin
structures in living cells and do not co-sediment with F-actin.
The two, mapped ABSs in CaP are C-terminal of the CH
domain [35] and function autonomously. So, what role for
the CH domain in CaP? CaP binding to other cytoskeletal
components, including tubulin and the intermediate ¢lament
protein desmin has been reported and it has been hypothe-
sised that the binding sites on CaP reside within the CH
domain. Thus, CaP has been suggested to function as a scaf-
folding protein for cytoskeletal structures. So far, however,
overexpression experiments have failed to induce detectable
bundling of intermediate ¢laments or microtubules in trans-
fected cultured cells.
An alternative function for the CaP CH domain has come
from the laboratory of Kathy Morgan [36,37]. This group has
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shown a direct physical interaction of the CaP and K-actinin
CH domains with the MAP kinase signaling molecules ERK1
and ERK 2. This puts CaP in the position to function as an
adaptor molecule in signaling pathways, an attractive idea
since several type 3 CH domain-containing molecules are in-
deed present at di¡erent positions in the Rho-signaling path-
way. In this context it appears relevant that CaP has been
identi¢ed as a direct target for Rho-associated kinase
(ROCK), a multifunctional serine/threonine kinase involved
in the regulation of actomyosin-based contractility in smooth-
and non-muscle cells [38].
4.2. Vav family proteins
In the RhoGEF Vav the amino terminal type 3 CH domain
appears to have adopted yet another function and may act as
a regulatory domain. It has been suggested that it interacts
intramolecularly with another motif to sterically block the
docking site for Rho family GTPases in the DH^PH binding
interface [39]. Most notably, domain-swap experiments in
which the Vav CH domain has been replaced as a whole
with the analogous type 3 domain from either ARHGEF6
[40] or the actin-associated proteins CaP or SM22 (Kranewit-
ter and Gimona, unpublished) fail to ‘silence’ the protein back
to wild-type activation levels indicating that speci¢c residues
within the Vav CH domain may determine its cellular func-
tion. Actin association also seems not to be the essential func-
tion of the Vav CH domain since its deletion causes an in-
crease in the cytoskeletal association of Vav [41]. Fusion of
Vav to the entire functional ABD of K-actinin e⁄ciently
translocates the molecule to stress ¢bres but this mistargeting
has only marginal in£uence on the protein’s GEF activity
(Kranewitter and Gimona, unpublished). The structural data
presented recently on the DH^PH catalytic unit of Vav [42]
demonstrate further that the acidic region containing the crit-
ical residue Y174, C-terminal of the CH domain forms a helix
which becomes inserted between the DH and PH domains and
the authors of the study suggested that this intercalation
causes the functional block of Vav’s GEF activity. However,
some open questions still remain. Why are partial N-terminal
deletion mutants of Vav constitutively active despite the pres-
ence of the acidic domain (harbouring Y174) and part of the
CH domain? Where does the CH domain go in this process of
conformational change? Based on the above one might spec-
ulate that the CH domain regulates the positioning of the
acidic helix by regulated interactions with other domains on
the Vav molecule or by an intermolecular interaction with
other factors present in the Vav signaling complex. A candi-
date for this is the nucleotide dissociation inhibitor RhoGDI.
A homologue of this, LyGDI was found to interact with the
N-terminal region of Vav in two hybrid analyses and in pull
down assays in vitro, and partial deletion of the Vav CH
domain abolished this interaction [43]. The intriguing model
emerging from these data is that CH domain interactions
could potentially regulate GEF activity of certain exchange
factors.
4.3. KPIX/COOL/ARHGEF6
ARHGEF6 (also known as KPIX and Cool2; accession
number BAA04985, coding for a 773 residue protein) has
recently been identi¢ed as a dbl family GEF. Like Vav, ARH-
GEF6 contains an N-terminal type 3 CH domain, which is
closer to the Vav-speci¢c consensus than that of any other
type 3 CH domain. Most notably, the very amino terminal
A helix contains a number of residues conserved speci¢cally in
the two GEF families, and the loop connecting helix A and B
is of similar length. The relation with Vav is also striking,
considering the devastating e¡ect of an amino terminal dele-
tion within the ARHGEF 6 CH domain caused by the skip-
ping of exon 2. This deletion has been shown to cause massive
mental abnormalities in patients carrying this defect [44,45].
Yet, as discussed above, in domain swap experiments the
ARHGEF6 CH domain fails to functionally substitute for
the Vav 1 CH domain.
4.4. IQGAP family proteins
Considerably less information is available on the function
of the amino terminal type 3 CH domain in IQGAP. The CH
module of this Rho family GTPase activating molecule is
believed to directly interact with actin and thereby target
the molecule to the sites of actomyosin interaction, most
prominently the contractile ring at the budding site in yeast
[46,47]. However, this e¡ect appears to require the dimerisa-
tion of the molecule via the more C-terminal coiled-coil do-
main in IQGAP. This attractive idea awaits proof at the mo-
lecular level, but the possibility of an actin binding domain
being formed by the heterologous dimerisation of CH do-
mains from two separate molecules is interesting. Such a hy-
pothesis is supported in part by the apparent ability of CH
domains from type 1/2 ABDs to participate in 3D domain
swapping (see above).
5. The actopaxin/parvin family: type 4 and type 5 CH
domains?
With the help of yeast two hybrid screens several groups
have (almost simultaneously) described a novel family of
small focal adhesion-associated proteins termed actopaxin/
parvin/CH-ILKBP/A⁄xin/CLINT ([48^51]; C.E. Turner, per-
sonal communication). The proteins contain two unconven-
tional CH domains in ‘tandem’ which do not match the con-
sensus of the type 1/2 ABDs and are in addition separated by
a 60-residue linker region. Three genetic isoforms of actopax-
in/parvin (K, L and Q) have been identi¢ed [49]. CH-ILKBP is
identical to the L isoform, as is a⁄xin. CLINT, by contrast is
most homologous to L-parvin, but contains a unique amino
terminal extension. Sequence analysis demonstrates a higher
similarity of the ¢rst CH domain of actopaxin with the type 1
CH domain of spectrin, whereas the second CH domain ap-
pears to have more in common with the type 1 CH domain of
K-actinin. Hence, one of the names, parvin, was chosen to
document that this molecule might be a ‘tiny’ K-actinin [49].
However, in agreement with the analysis presented by Olski et
al. [49] both actopaxin/parvin CH domains form a separate
phylogenetic branch, similar to the CH domains of ¢mbrin.
Most remarkably, Turner et al. [48] characterised a conserved
paxillin binding site (PBS) in the loop between helices A and
B of actopaxin’s second CH domain. Paxillin can bind to the
second CH domains in the absence of the ¢rst (tentatively
named type 5 and type 4 CH domains, respectively), and
the second (type 5) CH domain of actopaxin (a⁄xin; CH-
ILKBP) also binds integrin-linked kinase (ILK), but does
not require the PBS for this binding. The speci¢city of this
latter interaction is further underscored by a prominent cellu-
lar localisation in both focal and ¢bre-like adhesions, but also
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by the abolition of ILK binding (and adhesion localisation)
by a single point mutation of F271D in the type 5 CH domain
[51]. Assuming the general fold of a CH domain, this phenyl-
alanine residue (which is unique to the K and L actopaxins/
parvins) resides in the centre of the A helix in close proximity
to the autonomous PBS. However, recent studies by Nikolo-
poulos and Turner ([52] ; C.E. Turner, personal communica-
tion) have seriously questioned the e¡ectiveness of this muta-
tion for ILK binding and focal adhesion targeting of
actopaxin/parvin and these authors suggested that the
F271D mutation rather a¡ects paxillin binding due to struc-
tural perturbation of the neighbouring PBS. The actin binding
potential of actopaxin/parvin proposed to reside in the
N-terminal type 4 CH domain still requires some additional
investigation.
6. Conclusions
6.1. Structure/function
CH domains display an unusually high structural conserva-
tion but appear, by comparison, to be highly diverse in their
biological functions. To fully understand the variety of func-
tions displayed by the several CH domains more information
on the atomic structure of the module is needed. The ¢rst (A)
helix of the CH domain and the region bridging between helix
A and helix B may contain the relevant information for func-
tional diversity while the more C-terminal (C, F and G) heli-
ces may contribute primarily to the structural conservation. In
accordance with this assumption the most prominent di¡er-
ences between the ¢ve CH domain families are found in the
A^B loop (e.g. DFRXXL and PiP binding motifs in type 1
and type 2 CH domains in K-actinins; 5^7 residue inserts in
the type 3 CH domains of GEF family proteins; functional
ILK and PBSs in the type 5 CH domains of actopaxin/par-
vin), and even entire individual subfamilies (like K-actinin,
plectin, CaP, Vav etc.) display unique conserved residues in
the A helix.
Our understanding of the potential in£uence of the type 2
CH domains is only in its infancy. With a better understand-
ing of how certain types of CH domains can contribute to
protein function we will be able in the future to create chimera
to investigate the level of independence and cooperativity be-
tween the individual CH domains in an ABD. The discovery
of the CH domain has fuelled a new branch of research on
ABDs, the impact of which may be only appreciated in the
years to come. Certainly, we may expect new insights into the
alteration, stabilisation and dynamics of actin structures (and
possibly also other cytoskeletal components) by CH domains
in the near future and it is conceivable that CH domain family
proteins play a considerable role in the regulation of the cy-
toskeleton and as adaptors and regulators for signaling mol-
ecules.
6.2. Evolution
CH domains represent a conserved structural unit used in a
variety of modes to display di¡erent functions on its surface.
The potential involvement of CH domains in regulating the
actin cytoskeleton, but potentially also of microtubules and
intermediate ¢laments may be taken as support of the above.
The general principle of polymer formation and the resulting
exposure of interfaces along the surface of these polymers may
be directly related to the conservation of a general structure,
able to recognise these sites. Thus, the evolutionary aspect of
CH domain function adds another facet to the issue. Both
single type 3 and tandem type 1 and type 2 CH domain
proteins have been identi¢ed from yeast to man.
The phylogenetic tree in Fig. 4, based on a structure-ori-
ented sequence alignment of CH domains clearly reveals the
¢ve subfamilies described above. Three have already been
identi¢ed before [3,53]. The inclusion of recently discovered
proteins of the actopaxin/parvin family in the sequence anal-
ysis revealed two new types of CH domains. The ¢rst three
branches correspond to the CH domains of the cytoskeletal
actin binding proteins and to the type 3 CH domains of the
CaP family, and of some signaling proteins, respectively. The
branching of the CH domain tree must have functional im-
plications. It is, however, not possible to say whether the
group of single CH domains is evolutionarily closer to the
type 1 or type 2 branch. It is conceivable that the type 2
CH domain of actin binding proteins lost its function and
adopted an auxiliary role after an ancient duplication event.
Sequence analysis of the entire actin binding region composed
of two consecutive CH domains [3] shows close similarity
between proteins that bind to intermediate ¢laments (dysto-
nin, ACF7 and plectin), and the proteins of the spectrin fam-
ily. In plectin, a domain following the actin binding region is
homologous to the ¢rst structural repeat of spectrin. This
suggests that proteins of the plectin family acquired their actin
binding region from an ancestor similar to spectrin by a shuf-
£ing mechanism. Another interesting aspect concerns the pos-
sible duplication of the actin binding region of ¢mbrin. The
inspection of the evolutionary tree indicates that such an event
was relatively early, taking place before the divergence of
human ¢mbrin and its yeast homologue Sac6p.
6.3. Future prospects
The tendency with which we are able to extrapolate from
the current status of knowledge points towards a speci¢c func-
tion for CH domains in almost every molecular subfamily.
CH domains in Vav likely perform di¡erent functions than
they do in IQGAPs. Even actin binding ABDs are likely to
function di¡erently and are certainly regulated by di¡erent
molecular processes (compare K-actinin and ¢lamin). A de-
tailed analysis of the relative in£uences and contribution of
the individual CH domains is required in order to understand
the functions of this module. Comprehensive domain swap
studies may help in the future to reveal the enigmatic relation-
ships of the type 1/type 2 CH domains of ABDs and may help
to explain how single CH domains function. Studies on the
CH domain may have already come a long way since its
conception in 1995, but our understanding of the functional
diversity of this module is still in its infancy and there is
certainly a lot further to go to maturity.
Acknowledgements: We thank Christopher Turner for communicating
data on the actopaxin PBS motif prior to publication. This review is
dedicated to the memory of Matti Saraste.
References
[1] de Arruda, M.V., Watson, S., Lin, C.S., Leavitt, J. and Matsu-
daira, P. (1990) J. Cell Biol. 111, 1069^1079.
[2] Castresana, J. and Saraste, M. (1995) FEBS Lett. 374, 149^151.
[3] Banuelos, S., Saraste, M. and Djinovic-Carugo, K. (1998) Struc-
ture 6, 1419^1431.
FEBS 25624 21-2-02 Cyaan Magenta Geel Zwart
M. Gimona et al./FEBS Letters 513 (2002) 98^106 105
[4] Gimona, M. and Winder, S.J. (1998) Curr. Biol. 8, R674^675.
[5] Way, M., Pope, B. and Weeds, A.G. (1992) J. Cell Biol. 119,
835^842.
[6] Winder, S.J., Hemmings, L., Maciver, S.K., Bolton, S.J., Tinsley,
J.M., Davies, K.E., Critchley, D.R. and Kendrick-Jones, J.
(1995) J. Cell Sci. 108, 63^71.
[7] Djinovic-Carugo, K., Banuelos, S. and Saraste, M. (1997) Nat.
Struct. Biol. 4, 175^179.
[8] Keep, N.H., Winder, S.J., Moores, C.A., Walke, S., Norwood,
F.L.M. and Kendrick-Jones, J. (1999) Struct. Fold. Design 7,
1539^1546.
[9] Moores, C.A., Keep, N.H. and Kendrick-Jones, J. (2000) J. Mol.
Biol. 297, 465^480.
[10] Goldsmith, S.C., Pokala, N., Shen, W., Fedorov, A.A., Matsu-
daira, P. and Almo, S.C. (1997) Nat. Struct. Biol. 4, 708^712.
[11] Keep, N.H., Norwood, F.L.M., Moores, C.A., Winder, S.J. and
Kendrick-Jones, J. (1998) J. Mol. Biol. 285, 1257^1264.
[12] Norwood, F.L.M., Sutherland-Smith, A.J., Keep, N.H. and Ken-
drick-Jones, J. (2000) Struct. Fold. Design 8, 481^491.
[13] Rybakova, I.N., Amman, K.J. and Ervasti, J.M. (1996) J. Cell
Biol. 135, 661^672.
[14] Rybakova, I.N. and Ervasti, J.M. (1997) J. Biol. Chem. 272,
28771^28778.
[15] Schulunegger, M., Bennet, M. and Eisenberg, D. (1997) Adv.
Protein Chem. 50, 61^122.
[16] Fukami, K., Furuhashi, K., Inagaki, M., Endo, T., Hatano, S.
and Takenawa, T. (1992) Nature 359, 150^152.
[17] Fukami, K., Endo, T., Imamura, M. and Takenawa, T. (1994)
J. Biol. Chem. 269, 1518^1522.
[18] Fukami, K., Sawada, N., Endo, T. and Takenawa, T. (1996)
J. Biol. Chem. 271, 2646^2650.
[19] Furuhashi, K., Inagaki, M., Hatano, S., Fukami, K. and Take-
nawa, T. (1992) Biochem. Biophys. Res. Commun. 184, 1261^
1265.
[20] Mejean, C., Lebart, M.-C., Roustan, C. and Benyamin, Y. (1995)
Biochem. Biophys. Res. Commun. 210, 152^158.
[21] Smith, L., Su, X., Lin, P.-J., Zhi, G. and Stull, J.T. (1999) J. Biol.
Chem. 274, 29433^29438.
[22] Hatch, V., Zhi, G., Smith, L., Stull, J.T., Craig, R. and Lehman,
W. (2001) J. Cell Biol. 154, 611^617.
[23] Bonet-Kerrache, A., Fabbrizio, E. and Mornet, D. (1994) FEBS
Lett. 355, 49^53.
[24] Jarrett, H.W. and Foster, J.L. (1995) J. Biol. Chem. 270, 5578^
5586.
[25] Winder, S.J., Hemmings, L., Bolton, S.J., Maciver, S.K., Tinsley,
J.M., Davies, K.E., Critchley, D.R. and Kendrick-Jones, J.
(1995) Biochem. Soc. Trans. 23, S397.
[26] Winder, S.J. and Kendrick-Jones, J. (1995) FEBS Lett. 357, 125^
128.
[27] Izaguirre, G., Aguirre, L., Hu, Y., Lee, H., Schlaepfer, D., Anes-
kievich, B. and Haimovich, B. (2001) J. Biol. Chem. 276, 28676^
28685.
[28] Morris, G.E., Man, N.t., Huyen, N.t.N., Pereboev, A., Kendrick-
Jones, J. and Winder, S.J. (1999) Biochem. J. 337, 119^123.
[29] van der Loop, F.T., Schaart, G., Timmer, E.D., Ramaekers, F.C.
and van Eys, G.J. (1996) J. Cell Biol. 134, 141^401.
[30] Hanein, D., Matsudaira, P. and Rosier, D.J.D. (1997) J. Cell
Biol. 139, 387^396.
[31] Hanein, D. et al. (1998) Nat. Struct. Biol. 5, 787^792.
[32] Volkman, N., DeRosier, D., Matsudaira, P. and Hanein, D.
(2001) J. Cell Biol. 153, 947^956.
[33] Kovar, D.R., Staiger, C.J., Weaver, E.A. and McCurdy, D.W.
(2000) Plant J. 24, 625^636.
[34] Correia, I., Chu, D., Goldman, R.D. and Matsudaira, P. (1999)
J. Cell Biol. 146, 831^842.
[35] Gimona, M. and Mital, R. (1998) J. Cell Sci. 111, 1813^1821.
[36] Leinweber, B.D., Leavis, P.C., Grabarek, Z., Wang, C.-L. and
Morgan, K.G. (1999) Biochem. J. 34, 117^123.
[37] Menice, C.B., Hulvershorn, J., Adam, L.P., Wang, C.-L.A. and
Morgan, K.G. (1997) J. Biol. Chem. 272, 25157^25161.
[38] Kaneko, T., Amano, M., Maeda, A., Goto, H., Takahashi, K.,
Ito, M. and Kaibuchi, K. (2000) Biochem. Biophys. Res. Com-
mun. 273, 110^116.
[39] Abe, K., Whitehead, I.P., O’Bryan, J.P. and Der, C.J. (1999)
J. Biol. Chem. 274, 30410^30418.
[40] Billadeau, D.D., Mackie, S.M., Schoon, R.A. and Leibson, P.J.
(2000) J. Immunol. 164, 3971^3981.
[41] Kranewitter, W.J. and Gimona, M. (1999) FEBS Lett. 45, 123^
129.
[42] Aghazadeh, B., Lowry, W.E., Huang, X.Y. and Rosen, M.K.
(2000) Cell 102, 625^633.
[43] Groysman, M., Russek, C.S. and Katzav, S. (2000) FEBS Lett.
467, 75^80.
[44] Kutsche, K., Yntema, H., Brandt, A., Jantke, I., Nothwang,
H.G., Orth, U., Boavida, M.G., David, D., Chelly, J., Fryns,
J.P., Moraine, C., Ropers, H.H., Hamel, B.C., van Bokhoven,
H. and Gal, A. (2000) Nat. Genet. 26, 247^250.
[45] Lower, K.M. and Gecz, J. (2001) Am. J. Med. Genet. 100, 43^
48.
[46] Lippincott, J. and Li, R. (1998) J. Cell Biol. 140, 355^366.
[47] Shannon, K.B. and Li, R. (1999) Mol. Biol. Cell 10, 283^
296.
[48] Nikolopoulos, S.N. and Turner, C.E. (2000) J. Cell Biol. 151,
1435^1447.
[49] Olski, T.M., Noegel, A.A. and Korenbaum, E. (2000) J. Cell Sci.
114, 525^538.
[50] Yamaji, S., Suzuki, A., Sugiyama, Y., Koide, Y., Yoshida, M.,
Kanamori, H., Mohri, H., Ohno, S. and Ishigatsubo, Y. (2001)
J. Cell Biol. 153, 1251^1264.
[51] Tu, Y., Huang, Y., Zhang, Y., Hua, Y. and Wu, C. (2001) J. Cell
Biol. 153, 585^598.
[52] Nikolopoulos, S.N. and Turner, C.E. (2001) J. Biol. Chem. 276,
23499^23505.
[53] Stradal, T., Kranewitter, W., Winder, S.J. and Gimona, M.
(1998) FEBS Lett. 432, 134^137.
[54] Kraulis, P.J. (1991) J. Appl. Cryst. 24, 946^950.
[55] Merritt, E.A. and Murphy, M.E.P. (1994) Acta Crystallogr. D
50, 869^873.
FEBS 25624 21-2-02 Cyaan Magenta Geel Zwart
M. Gimona et al./FEBS Letters 513 (2002) 98^106106
